White-light endoscopy is the most common method for visually diagnosing early signs of gastric cancer in hospitals. Images of the stomach lining are displayed on the system monitor to guide the doctors on the best sites to take biopsies. The biopsies will confirm the diagnosis after a few days.
The delay in diagnosis is because conventional white light endoscopy cannot accurately differentiate normal vs cancerous tissues.
Difficult to differentiate between normal tissue (left) and
cancerous tissue (right) under conventional white light endoscopy.
Raman Spectral Analysis is a technique capable of capturing molecular information associated with the cellular metabolic constituents when the tissue molecules are excited by light energy directed at the tissue.
With the technology, the system is able to help identify tissue with high probability of having gastric cancer.
Spectra IMDx enables in-vivo molecular diagnosis for early gastric cancer. Using Raman Spectroscopy, the system provides objective, real-time feedback for physician to determine risk of gastric cancer, leading to improved early gastric cancer detection.
Cancer states are considered as having dysplasia or adenocarcinoma.
Non-cancer states are considered as intestinal metaplasia or normal state.
CANCER VS NON-CANCER
SPECTRA IMDx™ enables in-vivo molecular diagnosis for early gastric cancer. Using Raman spectroscopy, the system provides objective, real-time feedback for physicians to determine probability of the patient having gastric cancer, leading to improved early gastric cancer diagnosis.
SPECTRA IMDx™ classifies high grade dysplasia and gastric cancer as high risk, and gastritis, intestinal metaplasia, and low grade dysplasia as low risk. High risk lesions are generally treated with resection while low risk lesions can be closely followed up.